Relay Therapeutics Inc
NASDAQ:RLAY

Watchlist Manager
Relay Therapeutics Inc Logo
Relay Therapeutics Inc
NASDAQ:RLAY
Watchlist
Price: 4.34 USD 4.33% Market Closed
Market Cap: 726.4m USD
Have any thoughts about
Relay Therapeutics Inc?
Write Note

Relay Therapeutics Inc
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Relay Therapeutics Inc
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Relay Therapeutics Inc
NASDAQ:RLAY
Common Stock
$127k
CAGR 3-Years
8%
CAGR 5-Years
-81%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Common Stock
$18m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Common Stock
$33.4B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Common Stock
$2.6m
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
3%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Common Stock
$101.8k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Relay Therapeutics Inc
Glance View

Market Cap
724.3m USD
Industry
Biotechnology

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 245 full-time employees. The company went IPO on 2020-07-16. The firm is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The firm is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008, RLY-2608 and RLY-1971. Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008, is it inhibitor of fibroblast growth factor receptor 2 (FGFR2), enriched for patients with advanced solid tumors having oncogenic FGFR2. The firm uses its Dynamo platform to focus on precision oncology. The company is also advancing several early programs focused on other precision oncology and genetic disease targets.

RLAY Intrinsic Value
1.89 USD
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Relay Therapeutics Inc's Common Stock?
Common Stock
127k USD

Based on the financial report for Dec 31, 2023, Relay Therapeutics Inc's Common Stock amounts to 127k USD.

What is Relay Therapeutics Inc's Common Stock growth rate?
Common Stock CAGR 5Y
-81%

Over the last year, the Common Stock growth was 27%. The average annual Common Stock growth rates for Relay Therapeutics Inc have been 8% over the past three years , -81% over the past five years .

Back to Top